Unlabelled: The primary objective of this study was to evaluate the real-world effectiveness, side effects and challenges associated with the implementing of the groundbreaking BPaL-containing regimen in Thailand. Another aim was to investigate the characteristics and severity of the disease, the presence of abnormal extensive lesions in chest X-Rays and the influence of cavitation on sputum conversion.
Material And Method: The case series study included patients at TB clinic of Central chest institute of Thailand between August 2021-April 2023. All 28 Patients fullfilled the diagnostic criterial for MDR-TB by molecular tests and/or sputum culture. Sputum molecular test, utilizing GeneXpert MRB/XDR or Genotype MTBDRsl assay, was conducted. The 8 Pre-XDR patients who exhibited quinolone resistance and the 2 MDR-TB patients who encountered side effected from quinolone drugs were treated with BPaL regimen, while the remainder received BPaLM regimens.
Results: Among the 28 patients, 23 (82.1 %) successfully completed the treatment with favorable outcomes. However, one patient from the BpaL regimen died due to severe destroy lung lesion, and four patients from the BpalM regimen discontinued treatment. The investigation into the correlation between extension lesion, cavitation lesions, and culture conversion unveiled that the group with extension lesions and cavitation ≥4 cm had a diminished probability of achieving sputum culture conversion within 8 weeks in comparison to the group without attributes. The associated risk ratio was 0.56 (95 % CI, 0.14-2.27), p = 0.14. Although the study report minimal side effects, 6 patients (22.2 %) experienced peripheral neuropathy and a notable adverse reaction identified was optic neuritis, affecting 2 cases (7.1 %).
Summary: The administration of the BPaL-containing regimen resulted in rapid sputum conversion within 8 weeks and had minimal side effects.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10788258 | PMC |
| http://dx.doi.org/10.1016/j.jctube.2023.100408 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Estimating the Early Transmission Inhibition of new treatment regimens for drug-resistant tuberculosis.
J Infect Dis
January 2025
Division of Global Health Equity, Brigham and Women's Hospital, Boston, MA, United States.
Introduction: Most drug-resistant tuberculosis (DR-TB) occurs due to transmission of unsuspected or ineffectively treated DR-TB. The duration of treatment to stop person-to-person spread of DR-TB is uncertain. We evaluated the impact of novel regimens, including BPaL, on DR-TB transmission using the human-to-guinea pig (H-GP) transmission model.
View Article and Find Full Text PDFTB Anywhere, TB Everywhere. The First Case of pre-Extensively Drug Resistant Tuberculosis Treated with BPaL in Italy: Challenges and Opportunities for Transborder Collaboration.
Microb Drug Resist
January 2025
Regional TB Reference Centre, Villa Marelli Institute, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Even if in the past years new effective, safe, and orally administrable drugs are available to create shorter regimens, drug-resistant (DR) tuberculosis (TB) treatment remains a critical issue and a major challenge faced by clinicians worldwide. We present the first case of transborder pulmonary pre-extensively drug-resistant (pre-XDR)-TB treated in Italy with the bedaquiline-pretomanid-linezolid regimen. Diagnosis and treatment were started in Ukraine, and, after a month of treatment, due to the Russo-Ukrainian war, the patient moved to Italy, where the diagnosis was confirmed both by genotypic and phenotypic drug susceptibility tests, and treatment continued.
View Article and Find Full Text PDFStructural toxicity relationship (STR) of linezolid to mitigate myelosuppression and serotonergic toxicity.
Bioorg Med Chem
November 2024
Division of Computer Aided Drug Design, Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dhule 425405, Maharashtra, India. Electronic address:
Article Synopsis
- * Linezolid is an effective drug in the BPaL regimen for treating these resistant TB strains, but its use can be limited due to side effects like myelosuppression and MAO inhibition.
- * Research is focusing on modifying Linezolid and its analogues to reduce toxic effects while maintaining their antibacterial effectiveness, leading to the development of safer alternatives for treating drug-resistant TB.
Introducing BPaL: Experiences from countries supported under the LIFT-TB project.
PLoS One
November 2024
KNCV Tuberculosis Foundation, The Hague, The Netherlands.
Article Synopsis
- * The LIFT-TB project, involving 7 countries, focused on implementing BPaL under operational research conditions, aiming to assess its feasibility, effectiveness, and safety for selected DR-TB patients.
- * Interim results from November 2020 to March 2023 indicate a high treatment success rate of 90.9% among 574 enrolled patients, with manageable adverse effects and no unexpected complications, demonstrating the
Experience of piloting BPaLM/BPaL for DR-TB care at selected sites in Pakistan.
IJTLD Open
November 2024
Association for Social Development, Islamabad, Pakistan.
Background: Pakistan ranks fourth globally in terms of high drug-resistant TB (DR-TB) burden, with approximately one-third of cases resistant to fluoroquinolones. Bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM/BPaL) offers an opportunity for most DR-TB patients to benefit from a shorter, all-oral, well-tolerated and more effective treatment.
Methods: We conducted a retrospective cohort study to pilot the BPaLM/BPaL regimen at four selected sites in two provinces of Pakistan, i.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!